Mutant HER2 needs mutant HER3 to be an effective oncogene

Hanker et al. reveal that co-occurring missense mutations in the human epidermal growth factor receptor 2 (HER2) and its catalytically inactive homolog HER3 synergize to promote oncogenic signaling by the HER2/HER3 complex.

Detalles Bibliográficos
Autores principales: Trenker, Raphael, Diwanji, Devan, Jura, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385292/
https://www.ncbi.nlm.nih.gov/pubmed/34467245
http://dx.doi.org/10.1016/j.xcrm.2021.100361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385292/
https://www.ncbi.nlm.nih.gov/pubmed/34467245
http://dx.doi.org/10.1016/j.xcrm.2021.100361

Ejemplares similares